Navigation Links
For cancer cells, genetics alone is poor indicator for drug response
Date:4/12/2009

BOSTON, Mass. (April 12, 2009) In certain respects, cells are less like machines and more like people. True, they have lots of components, but they also have lots of personality. For example, when specific groups of people are studied in aggregate (conservatives, liberals, atheists, evangelicals), they appear to be fairly uniform and predictable. But when looked at one person at a time, individuals often break the preconceptions.

Same with cells.

Researchers tend to identify characteristics of particular cells by looking at millions at a time. As a result, they'll find that, say, "group A" responds very well to a particular cancer treatment, whereas "group B" does not. They will then often compare group A to group B to find out why.

But often ignored is that not every cell in either group behaves in ways that the aggregate indicates. In a group of cells shown to be vulnerable to a particular cancer treatment, perhaps 10 percent resist it while 90 percent succumb. While researchers have offered various explanations for this, few have studied it.

Now a group of scientists in the lab of Harvard Medical School Professor of Systems Biology Peter Sorger have studied such "outlier" cells in the context of a new and highly touted cancer drug. They have found that vastly disparate reactions occur within genetically homogeneous cell groups. These discrepancies result from protein levels that vary from cell to cell, even among cells that are identical genetic twins. What's more, these protein levels and their subsequent traits can be passed down to daughter cellsa heritability that has nothing to do with genetics.

"Genetics are permanently heritable, while these protein levels are temporarily heritable," says Sorger. "But this temporary inheritance can make all the difference in the world when it comes to the effectiveness of certain medications."

These findings are published April 12 online in Nature. '/>"/>

Contact: David Cameron
david_cameron@hms.harvard.edu
617-432-0441
Harvard Medical School
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. New drug shows promise in treating drug-resistant prostate cancer
2. NC State researchers find soy may aid in treating canine cancers
3. New medications show promise in treating drug-resistant prostate cancer
4. TGen helps promote cancer awareness for vast Navajo Nation
5. Compendium of pancreatic cancer biomarkers established as strategic approach to early-detection
6. Novel lung cancer vaccine shows promise in fighting early-stage lung cancer
7. Broccoli sprouts may prevent stomach cancer by defeating Helicobacter pylori
8. Fluorescent cancer cells to guide brain surgeons
9. UC Davis researchers identify a protein that may help breast cancer spread, beat cancer drugs
10. Health choices predict cancer survival, U-M study finds
11. Taste, odor intervention improves cancer therapy, according to Virginia Tech, Wake Forest study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/11/2015)... , May 11, 2015 Curemark LLC, a ... start of a new Phase III double blind, randomized, ... novel formulation, CM-AT, on all children ages 3-8 with ... FDA Phase III double blinded clinical trial for CM-AT ... levels of the digestive enzyme chymotrypsin. This new trial ...
(Date:5/8/2015)... Synaptics Inc. (NASDAQ: SYNA ), the leading ... the executive management team will present at the following investor ... Telecom Conference Date: May 18, 2015 Time: 10:40am ... Cowen and Company Technology, Media & ... The New York Palace Hotel, New York, NY ...
(Date:5/6/2015)... , May 6, 2015 LifeBEAM, a ... established helmet producer, announced today that they will expand ... the world,s first bio-sensing cycling helmet and the first ... in two new colors in order to give cyclists ... product. In addition, LifeBEAM and Lazer announced their plan ...
Breaking Biology News(10 mins):Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2Synaptics to Present at Upcoming Investor Conferences 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 3
... Arizona farmers receive the same yield/acre, use fewer chemical ... biotech cotton known as Bt cotton, according to new ... study that simultaneously examined how growing Bt cotton affects ... the environment. , "What we see is that it's ...
... An important source of uncertainty in predictions about global ... carbon dioxide. Now biologists at the University of California, ... mechanism plants use to regulate their carbon dioxide intake. ... early on-line edition of the journal Proceedings of the ...
... Hughes Medical Institute (HHMI) international research scholar in Israel ... so hard to stop. , Emanuel Hanski, a ... found that the success of Group A Streptococcus is ... immune system's distress calls. The findings, published in the ...
Cached Biology News:Biotech cotton provides same yield with fewer pesticides 2Biotech cotton provides same yield with fewer pesticides 3UCSD study reveals how plants respond to elevated carbon dioxide 2UCSD study reveals how plants respond to elevated carbon dioxide 3Solved: The mystery of flesh-eating bacteria's relentless attack 2Solved: The mystery of flesh-eating bacteria's relentless attack 3
(Date:5/28/2015)... The Academy of Model Aeronautics Foundation will ... August 15, 2015. National Model Aviation Day was created to ... model flying to the general public. , The AMA has ... in the celebration by hosting events in their own communities. ... Aviation Day events. View our online event map to ...
(Date:5/28/2015)... May 28, 2015 Natera, Inc., a ... study published in Ultrasound in Obstetrics & ... (SNP)-based non-invasive prenatal test (NIPT) can identify a ... A study based upon data collected ... occur in about 1 in 1,000 pregnancies, although ...
(Date:5/28/2015)... TX (PRWEB) May 28, 2015 ... association serving and representing the life sciences industry ... Board of Directors meeting at The Foundry in ... of the organization brought together a broad spectrum ... and underscored the organization's early successes in partnering ...
(Date:5/28/2015)... , May 28, 2015 RXi Pharmaceuticals Corporation ... discovering and developing innovative therapeutics, primarily in the areas ... a public offering of 26 million units at a ... gross proceeds of approximately $10.4 million. Each unit consists ... 13-month overallotment purchase right to purchase 0.50 of a ...
Breaking Biology Technology:Model flying pilots celebrate the Academy of Model Aeronautics Foundation’s Third Annual National Model Aviation Day 2First Confirmed Detection of a Complete Molar Pregnancy with Cell-Free DNA Test 2First Confirmed Detection of a Complete Molar Pregnancy with Cell-Free DNA Test 3BioNorthTX Holds Inaugural Board of Directors Meeting 2BioNorthTX Holds Inaugural Board of Directors Meeting 3RXi Pharmaceuticals Announces $10 Million Public Offering of Common Stock and Warrants 2RXi Pharmaceuticals Announces $10 Million Public Offering of Common Stock and Warrants 3
...  Today, the Global Probiotics Council (GPC), a committee formed ... launch of the fifth annual Young Investigator Grant for ... in the amount of $50,000, to promising young researchers. ... the role of probiotics and gastrointestinal microbiota in health ...
... Arcion Therapeutics, a clinical stage biotechnology company developing ... received notice of allowance for a US Patent for ... ARC-2022 is being developed by Arcion for pain associated ... has been evaluated in a single-dose Phase 1 pharmacokinetic ...
... Jan. 4, 2012  Verify Brand™ announces the release ... 4.0 software. VB Enterprise 4.0 is a suite ... client and mobile software applications that enable comprehensive ... Trace® across the supply chain. VB Enterprise ...
Cached Biology Technology:Fifth Cycle of Probiotics & Microbiota Research Grant Announced 2Fifth Cycle of Probiotics & Microbiota Research Grant Announced 3Fifth Cycle of Probiotics & Microbiota Research Grant Announced 4Arcion Receives Notice of Allowance for US Patent for Novel Topical Lidocaine Formulation for Pain 2Verify Brand™ Announces the Release of VB Enterprise 4.0 2
Mouse monoclonal antibody raised against a partial recombinant KRT4. NCBI Entrez Gene ID = KRT4...
Mouse monoclonal antibody raised against a partial recombinant ALPK3. NCBI Entrez Gene ID = ALPK3...
... Channel Cell Lines ,High Quality, Functionally-Validated, Ion ... well known for having a critical role ... have a key function in pain, CNS ... channels have been investigated in therapeutic areas, ...
... PrecisION Ion Channel Cell Lines ,High ... ,Ion channels are well known for having ... function and consequently have a key function ... that modulate ion channels have been investigated ...
Biology Products: